← All trials
NCT01656668
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2012
- Primary completion
- Aug 1, 2013
- Completion date
- Aug 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 288
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Respicopea LimitedLead sponsor
- Albany House Medical CentreOverall official - principal investigator
- Staploe Medical CentreOverall official - principal investigator
- Freeman Health SystemOverall official - principal investigator
- Sheepcot Medical CentreOverall official - principal investigator
- Mortimer SurgeryOverall official - principal investigator
- Ormeau Road Health CentreOverall official - principal investigator
- University of HullOverall official - principal investigator
- University of LeicesterOverall official - principal investigator
- Queen's University, BelfastOverall official - principal investigator
- University of LondonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.